Cardiovascular benefits associated with GLP 1 receptor agonists in patients with obesity
DOI:
https://doi.org/10.63688/mtbsjh44Keywords:
obesity, GLP-1 receptor agonists, cardiovascular risk, cardiovascular diseases, semaglutideAbstract
Introduction: Obesity is associated with an increased risk of developing cardiovascular diseases. Glucagon-like peptide-1 receptor (GLP-1) agonists have demonstrated beneficial effects on body weight and certain cardiovascular outcomes.
Objective: To synthesize the available scientific evidence on the cardiovascular benefits associated with GLP-1 receptor agonists in patients with obesity.
Methodology: A qualitative, descriptive narrative literature review was conducted using publications indexed in PubMed/MEDLINE, Scopus, and SciELO from January 2021 to September 2026. Studies published in English or Spanish evaluating GLP-1 receptor agonists in adults with overweight or obesity, with or without type 2 diabetes mellitus, were considered. Five studies were included in the review.
Results: The evidence examined showed benefits related to reductions in major adverse cardiovascular events, hospitalizations for heart failure, and certain cardiorenal outcomes. These effects may be associated with weight loss and improvements in metabolic risk factors, although the magnitude of benefit varies across the populations studied.
Conclusions: GLP-1 receptor agonists represent a relevant therapeutic option for obesity management and cardiovascular risk reduction in selected populations. Further studies are needed to clarify their benefits across different clinical profiles.
Downloads
References
Ahn, J., Song, J., Admire, K., Chang, Y., Chi, K.-Y., Gordon, N. T., & Sill, J. M. (2026). Glucagon-like peptide receptor agonists (GLP-1RAs) as cardiovascular risk modifiers in obstructive sleep apnea and obesity: A real-world study. Journal of Clinical Sleep Medicine, 22(1), Article 102. https://doi.org/10.1007/s44470-026-00110-x
Colhoun, H. M., Lingvay, I., Brown, P. M., Deanfield, J., Brown-Frandsen, K., Kahn, S. E., Plutzky, J., Node, K., Parkhomenko, A., Rydén, L., Wilding, J. P. H., Mann, J. F. E., Tuttle, K. R., Idorn, T., Rathor, N., & Lincoff, A. M. (2024). Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nature Medicine, 30(7), 2058–2066. https://doi.org/10.1038/s41591-024-03015-5
Deanfield, J., Verma, S., Scirica, B. M., Kahn, S. E., Emerson, S. S., Ryan, D. H., Lingvay, I., Colhoun, H. M., Plutzky, J., Kosiborod, M. N., Hovingh, G. K., Hardt-Lindberg, S. R., Frenkel, O., Weeke, P. E., Rasmussen, S., Goudev, A., Lang, C. C., Urina-Triana, M., Pietilä, M., & Lincoff, A. M. (2024). Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: A prespecified analysis of the SELECT trial. The Lancet, 404(10454), 773–786. https://doi.org/10.1016/S0140-6736(24)01498-3
Deanfield, J., Lincoff, A. M., Kahn, S. E., Emerson, S. S., Lingvay, I., Scirica, B. M., Plutzky, J., Kushner, R. F., Colhoun, H. M., Hovingh, G. K., Stensen, S., Weeke, P. E., Jeppesen, O. K., Bravo, R., Wu, C.-C., Komuro, I., Santini, F., Hjelmesæth, J., Urina-Triana, M., . . . Ryan, D. H. (2025). Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: A prespecified analysis of the SELECT trial. The Lancet, 406(10516), 2257–2268. https://doi.org/10.1016/S0140-6736(25)01375-3
Ghuman, A., & Das, M. (2026). Association of periprocedural GLP-1 receptor agonist therapy with 1-year major adverse cardiovascular events after carotid artery stenting: A propensity-matched analysis. Journal of the Society for Cardiovascular Angiography & Interventions, 5(6), Article 105387. https://doi.org/10.1016/j.jscai.2026.105387
Kong, F., Zhao, Y., Zhang, W., Wang, X., Wu, T., Zhou, Z., Xu, Y., Xia, L., & Sun, T. (2026). Comprehensive evaluation of GLP-1 receptor agonists: An umbrella review of clinical outcomes across multiple diseases. Nature Communications, 17(1), Article 972. https://doi.org/10.1038/s41467-025-67701-9
Lingvay, I., Deanfield, J., Kahn, S. E., Weeke, P. E., Toplak, H., Scirica, B. M., Rydén, L., Rathor, N., Plutzky, J., Morales, C., Lincoff, A. M., Lehrke, M., Jeppesen, O. K., Gajos, G., Colhoun, H. M., Cariou, B., & Ryan, D. H. (2024). Semaglutide and cardiovascular outcomes by baseline HbA1c and change in HbA1c in people with overweight or obesity but without diabetes in SELECT. Diabetes Care, 47(8), 1360–1369. https://doi.org/10.2337/dc24-0764
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S. R., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563
McEwan, P., Bøg, M., Faurby, M., Foos, V., Lingvay, I., Lübker, C., Miller, R., Toliver, J. C., Yeates, F., & Lincoff, A. M. (2025). Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes. Journal of Medical Economics, 28(1), 268–278. https://doi.org/10.1080/13696998.2025.2459529
Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Shah, S. J., Verma, S., Jensen, T. J., Einfeldt, M. N., Liisberg, K., Perna, E., Sharma, K., Ezekowitz, J. A., Fu, M., Melenovský, V., Ito, H., Lelonek, M., Kosiborod, M. N., & STEP-HFpEF Trial Committees and Investigators. (2024). Semaglutide and NT-proBNP in obesity-related HFpEF: Insights from the STEP-HFpEF program. Journal of the American College of Cardiology, 84(1), 27–40. https://doi.org/10.1016/j.jacc.2024.04.022
Platz, E., Kaplan, L. M., le Roux, C. W., Wharton, S., Burger, S., Hussain, S. A., Brueckmann, M., Startseva, E., Fey, C., Kosiborod, M. N., & Bozkurt, B. (2026). Survodutide for the treatment of obesity: Baseline characteristics of the SYNCHRONIZE cardiovascular outcomes trial. JACC: Heart Failure, 14(5), Article 102780. https://doi.org/10.1016/j.jchf.2025.102780
Polu, P. P. R. (2026). Revolutionizing obesity treatment: The emerging role of GLP-1 receptor agonists and next-generation pharmacotherapies. Obesity Medicine, 60, Article 100686. https://doi.org/10.1016/j.obmed.2026.100686
Smolderen, K. G., Mena-Hurtado, C., Divino, V., Zhao, Z., Chen, Y., Boland, J., Chao, A., Song, J., Smolarz, B. G., Knop, F. K., & Nanna, M. G. (2026). Association between semaglutide 2.4 mg and risk of cardiovascular events in people with overweight or obesity without atherosclerotic cardiovascular disease in the real-world: The SCORE—primary prevention study. American Journal of Preventive Cardiology, 27, Article 101521. https://doi.org/10.1016/j.ajpc.2026.101521
Verma, S., Butler, J., Borlaug, B. A., Davies, M. J., Kitzman, D. W., Shah, S. J., Petrie, M. C., Barros, E., Rönnbäck, C., Vestergaard, L. S., Schou, M., Ezekowitz, J. A., Sharma, K., Patel, S., Chinnakondepalli, K. M., & Kosiborod, M. N. (2024). Efficacy of semaglutide by sex in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF trials. Journal of the American College of Cardiology, 84(9), 773–785. https://doi.org/10.1016/j.jacc.2024.06.001
Wharton, S., Rosenstock, J., Konige, M., Lin, Y., Duffin, K., Wilson, J., Banerjee, H., Pirro, V., Kazda, C., & Mather, K. (2025). Treatment with orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes. Cardiovascular Diabetology, 24(1), Article 240. https://doi.org/10.1186/s12933-025-02781-x
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Roberta Alejandra Cedeño Zambrano, Daniel Andrés Andrade Párraga, Analia Lorena Velásquez Menoscal, Nagelly Marlyn Riofrio Díaz, Samuel Isaac Quimis Peñafiel (Autor/a)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Los artículos publicados en la revista se distribuyen bajo la licencia Creative Commons Atribución 4.0 Internacional (CC BY 4.0). Esta licencia permite a terceros descargar, copiar, distribuir, adaptar y reutilizar una obra, incluso con fines comerciales, siempre que se otorgue el crédito adecuado al autor original.
